Anti-IL2 receptor monoclonal antibody (33B3.1) in prophylaxis of early kidney rejection in humans: a randomized trial versus rabbit antithymocyte globulin

Transplant Proc. 1989 Feb;21(1 Pt 2):1769-71.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Animals
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antilymphocyte Serum / adverse effects
  • Antilymphocyte Serum / therapeutic use*
  • Clinical Trials as Topic
  • Communicable Diseases / etiology
  • Female
  • Graft Rejection*
  • Humans
  • Interleukin-2 / immunology*
  • Kidney Transplantation*
  • Male
  • Middle Aged
  • Rabbits / immunology
  • Random Allocation
  • Receptors, Interleukin-2 / immunology*

Substances

  • Antibodies, Monoclonal
  • Antilymphocyte Serum
  • Interleukin-2
  • Receptors, Interleukin-2